We believe in success through collaboration. We seek partnerships with leading biopharmaceutical companies that bring complementary capabilities and resources, with the goal of introducing potentially life-saving therapies to the market more efficiently. Through collaborations we can extend our reach beyond our 4DMT internal pipeline to additional disease indications. Our partners augment our capabilities through their disease area expertise and key opinion leader networks; strong intellectual property on promising transgene payloads and/or regulatory elements; financial resources applied to product R&D and biologics commercialization.
Our approach to partnering is principled and flexible. We prefer a creative approach to deal structuring that optimizes the benefit for both parties. Together with our partners, we design and execute a development and commercialization plan for our partnered products.
4DMT has entered into multiple corporate alliances, including partnerships with Roche, Pfizer and MedImmune (AstraZeneca).
Our biopharmaceutical partners provide the following strengths to our R&D programs:
Our product development and commercialization model is flexible, and we adapt it to fit each partnership. We engage with our partners to design and execute the best R&D and commercialization plan for the specific business relationship and disease targets. We select from two general collaboration models:
Our partnership with Roche is focused on the discovery and development of targeted and proprietary AAV products for use in ophthalmology indications.
Our partnership with Pfizer is focused on the discovery and development of targeted and proprietary AAV-based gene therapeutics expressing a specific transgene for use in patients with a large market chronic heart disease. Pfizer made a cash payment and an equity investment in 4DMT. Pfizer holds a seat on the Board of Directors. 4DMT retains all worldwide rights to cardiac-targeted vectors, to develop products for all non-partnered transgenes and for all indications in the heart.
Our research partnership with MedImmune (wholly-owned subsidiary of AstraZeneca) is focused on the discovery and development of aerosolized 4DMT AAV lung vectors to modulate a well-validated molecular target in a large market lung disease. 4DMT retains all other rights for lung disease, for 4DMT lung vectors and for modulation of any other molecular target in the lung.